This company listing is no longer active
IBT BTA B Stock Overview
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Infant Bacterial Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr56.20 |
| 52 Week High | kr64.00 |
| 52 Week Low | kr45.20 |
| Beta | 1.04 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.20% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IBT BTA B | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 19.6% | -5.7% | -1.6% |
| 1Y | n/a | 58.1% | 7.8% |
Return vs Industry: Insufficient data to determine how IBT BTA B performed against the Swedish Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IBT BTA B performed against the Swedish Market.
Price Volatility
| IBT BTA B volatility | |
|---|---|
| IBT BTA B Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: IBT BTA B has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IBT BTA B's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Staffan Stromberg | www.ibtherapeutics.com |
Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants.
Infant Bacterial Therapeutics AB (publ) Fundamentals Summary
| IBT BTA B fundamental statistics | |
|---|---|
| Market cap | kr800.20m |
| Earnings (TTM) | -kr68.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.6x
P/E RatioIs IBT BTA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBT BTA B income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr68.72m |
| Earnings | -kr68.72m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 25, 2023
| Earnings per share (EPS) | -5.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IBT BTA B perform over the long term?
See historical performance and comparison